南京英派药业股份有限公司（07630）8月19日在港交所公告称，公司董事会将于2026年8月31日（星期一）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布事宜。
公告显示，截至本公告日期，公司董事会由3名执行董事、3名非执行董事及3名独立非执行董事组成。执行董事包括蔡遂雄博士（兼首席执行官）、田野博士及马宁女士；非执行董事为徐聪博士、Qiang Xu博士及刘涛先生；独立非执行董事为郭明博士、萧志雄先生及邵黎明博士。
公司提醒投资者关注相关业绩公告发布时间，并据此评估可能产生的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.